Clinical trial finalisation activities are well advanced for Starpharma’s two recently completed Phase 2 clinical trials of DEP® cabazitaxel and DEP® docetaxel as monotherapy. Top-line results are expected to be announced in Q3 CY23.
We are already 1 month into Q3.
Expect topline results in the next two months.
Lets hope for positive results or I fear that this company could be GOOOOOOOOOOOONE along with all of our hard earned $'s.....
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
